Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease

Kai Yuan Tzen, Shieh-Yueh Yang, Ta Fu Chen, Ting Wen Cheng, Herng-Er Horng, Hsiang Ping Wen, Ya Yao Huang, Chyng Yann Shiue, Ming Jang Chiu

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Recent advances in biomarkers provide the possibility of early or preclinical diagnosis of Alzheimer's pathology. Currently, decreased levels of Aβ-42 and increased levels of tau proteins in cerebral spinal fluid are considered reliable biomarkers of Alzheimer's disease (AD); however, little evidence exists for the use of amyloid and tau protein levels in the plasma as useful biomarkers. We investigated the potential use of plasma biomarkers to diagnose AD and explored their relationships with brain Aβ deposition in amyloid imaging. We used an immunomagnetic reduction assay to measure the plasma levels of Aβ40, Aβ42, and tau proteins in 20 older control participants and 25 participants who had either mild cognitive impairment due to AD or early AD dementia. All participants received 11C-labeled Pittsburgh compound B PET scans. The sensitivity of the plasma tau level at the cutoff value of 28.27 pg/mL was 92%, and the specificity was 100%; the sensitivity of the Aβ42/40 ratio at the cutoff value of 0.3693 was 84%, and the specificity was 100%. Regression analyses of the effects of plasma protein levels on brain amyloid retention, as determined by standard uptake value ratios in either side of the frontal, parietal, and temporal lobes and the precuneus, are predicted only by ratios of plasma Aβ42/40 (R2 0.326-0.449, all p < 0.001) but not by plasma tau levels. Plasma Aβ in terms of Aβ42/40 might provide an indirect estimation of Aβ deposition in the brain.

Original languageEnglish
Pages (from-to)830-836
Number of pages7
JournalACS Chemical Neuroscience
Volume5
Issue number9
DOIs
Publication statusPublished - 2014 Sep 17

Fingerprint

Brain
Alzheimer Disease
Plasmas
Biomarkers
tau Proteins
Parietal Lobe
Amyloid
Amyloidogenic Proteins
Frontal Lobe
Pathology
Temporal Lobe
Positron-Emission Tomography
Blood Proteins
Assays
Regression Analysis
Imaging techniques
Fluids

Keywords

  • <sup>11</sup>C-PiB
  • AD pathology
  • Beta amyloid
  • Cognitive function
  • Mild cognitive impairment
  • Plasma biomarker
  • Tau

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Tzen, K. Y., Yang, S-Y., Chen, T. F., Cheng, T. W., Horng, H-E., Wen, H. P., ... Chiu, M. J. (2014). Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. ACS Chemical Neuroscience, 5(9), 830-836. https://doi.org/10.1021/cn500101j

Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. / Tzen, Kai Yuan; Yang, Shieh-Yueh; Chen, Ta Fu; Cheng, Ting Wen; Horng, Herng-Er; Wen, Hsiang Ping; Huang, Ya Yao; Shiue, Chyng Yann; Chiu, Ming Jang.

In: ACS Chemical Neuroscience, Vol. 5, No. 9, 17.09.2014, p. 830-836.

Research output: Contribution to journalArticle

Tzen, KY, Yang, S-Y, Chen, TF, Cheng, TW, Horng, H-E, Wen, HP, Huang, YY, Shiue, CY & Chiu, MJ 2014, 'Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease', ACS Chemical Neuroscience, vol. 5, no. 9, pp. 830-836. https://doi.org/10.1021/cn500101j
Tzen, Kai Yuan ; Yang, Shieh-Yueh ; Chen, Ta Fu ; Cheng, Ting Wen ; Horng, Herng-Er ; Wen, Hsiang Ping ; Huang, Ya Yao ; Shiue, Chyng Yann ; Chiu, Ming Jang. / Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. In: ACS Chemical Neuroscience. 2014 ; Vol. 5, No. 9. pp. 830-836.
@article{d9e2eac6d7d2444ba15c312457f6de8f,
title = "Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease",
abstract = "Recent advances in biomarkers provide the possibility of early or preclinical diagnosis of Alzheimer's pathology. Currently, decreased levels of Aβ-42 and increased levels of tau proteins in cerebral spinal fluid are considered reliable biomarkers of Alzheimer's disease (AD); however, little evidence exists for the use of amyloid and tau protein levels in the plasma as useful biomarkers. We investigated the potential use of plasma biomarkers to diagnose AD and explored their relationships with brain Aβ deposition in amyloid imaging. We used an immunomagnetic reduction assay to measure the plasma levels of Aβ40, Aβ42, and tau proteins in 20 older control participants and 25 participants who had either mild cognitive impairment due to AD or early AD dementia. All participants received 11C-labeled Pittsburgh compound B PET scans. The sensitivity of the plasma tau level at the cutoff value of 28.27 pg/mL was 92{\%}, and the specificity was 100{\%}; the sensitivity of the Aβ42/40 ratio at the cutoff value of 0.3693 was 84{\%}, and the specificity was 100{\%}. Regression analyses of the effects of plasma protein levels on brain amyloid retention, as determined by standard uptake value ratios in either side of the frontal, parietal, and temporal lobes and the precuneus, are predicted only by ratios of plasma Aβ42/40 (R2 0.326-0.449, all p < 0.001) but not by plasma tau levels. Plasma Aβ in terms of Aβ42/40 might provide an indirect estimation of Aβ deposition in the brain.",
keywords = "<sup>11</sup>C-PiB, AD pathology, Beta amyloid, Cognitive function, Mild cognitive impairment, Plasma biomarker, Tau",
author = "Tzen, {Kai Yuan} and Shieh-Yueh Yang and Chen, {Ta Fu} and Cheng, {Ting Wen} and Herng-Er Horng and Wen, {Hsiang Ping} and Huang, {Ya Yao} and Shiue, {Chyng Yann} and Chiu, {Ming Jang}",
year = "2014",
month = "9",
day = "17",
doi = "10.1021/cn500101j",
language = "English",
volume = "5",
pages = "830--836",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease

AU - Tzen, Kai Yuan

AU - Yang, Shieh-Yueh

AU - Chen, Ta Fu

AU - Cheng, Ting Wen

AU - Horng, Herng-Er

AU - Wen, Hsiang Ping

AU - Huang, Ya Yao

AU - Shiue, Chyng Yann

AU - Chiu, Ming Jang

PY - 2014/9/17

Y1 - 2014/9/17

N2 - Recent advances in biomarkers provide the possibility of early or preclinical diagnosis of Alzheimer's pathology. Currently, decreased levels of Aβ-42 and increased levels of tau proteins in cerebral spinal fluid are considered reliable biomarkers of Alzheimer's disease (AD); however, little evidence exists for the use of amyloid and tau protein levels in the plasma as useful biomarkers. We investigated the potential use of plasma biomarkers to diagnose AD and explored their relationships with brain Aβ deposition in amyloid imaging. We used an immunomagnetic reduction assay to measure the plasma levels of Aβ40, Aβ42, and tau proteins in 20 older control participants and 25 participants who had either mild cognitive impairment due to AD or early AD dementia. All participants received 11C-labeled Pittsburgh compound B PET scans. The sensitivity of the plasma tau level at the cutoff value of 28.27 pg/mL was 92%, and the specificity was 100%; the sensitivity of the Aβ42/40 ratio at the cutoff value of 0.3693 was 84%, and the specificity was 100%. Regression analyses of the effects of plasma protein levels on brain amyloid retention, as determined by standard uptake value ratios in either side of the frontal, parietal, and temporal lobes and the precuneus, are predicted only by ratios of plasma Aβ42/40 (R2 0.326-0.449, all p < 0.001) but not by plasma tau levels. Plasma Aβ in terms of Aβ42/40 might provide an indirect estimation of Aβ deposition in the brain.

AB - Recent advances in biomarkers provide the possibility of early or preclinical diagnosis of Alzheimer's pathology. Currently, decreased levels of Aβ-42 and increased levels of tau proteins in cerebral spinal fluid are considered reliable biomarkers of Alzheimer's disease (AD); however, little evidence exists for the use of amyloid and tau protein levels in the plasma as useful biomarkers. We investigated the potential use of plasma biomarkers to diagnose AD and explored their relationships with brain Aβ deposition in amyloid imaging. We used an immunomagnetic reduction assay to measure the plasma levels of Aβ40, Aβ42, and tau proteins in 20 older control participants and 25 participants who had either mild cognitive impairment due to AD or early AD dementia. All participants received 11C-labeled Pittsburgh compound B PET scans. The sensitivity of the plasma tau level at the cutoff value of 28.27 pg/mL was 92%, and the specificity was 100%; the sensitivity of the Aβ42/40 ratio at the cutoff value of 0.3693 was 84%, and the specificity was 100%. Regression analyses of the effects of plasma protein levels on brain amyloid retention, as determined by standard uptake value ratios in either side of the frontal, parietal, and temporal lobes and the precuneus, are predicted only by ratios of plasma Aβ42/40 (R2 0.326-0.449, all p < 0.001) but not by plasma tau levels. Plasma Aβ in terms of Aβ42/40 might provide an indirect estimation of Aβ deposition in the brain.

KW - <sup>11</sup>C-PiB

KW - AD pathology

KW - Beta amyloid

KW - Cognitive function

KW - Mild cognitive impairment

KW - Plasma biomarker

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84924935598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924935598&partnerID=8YFLogxK

U2 - 10.1021/cn500101j

DO - 10.1021/cn500101j

M3 - Article

C2 - 25054847

AN - SCOPUS:84924935598

VL - 5

SP - 830

EP - 836

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 9

ER -